Blacksburg, VA, United States of America

Gerhardt G Schurig

This inventor holds 6 USPTO granted patents and 3 published patent applications. Top assignees: Virginia Tech Intellectual Properties Inc., University of California, US Government as Represented by the Secretary of the Army. Active years: 2000-2019.

USPTO Granted Patents = 6 (Patent Applications = 3)

% Patents Active = 83.3

Average Co-Inventor Count = 5.2

ph-index = 3

Forward Citations = 26(Granted Patents)

Company Filing History:

3 out of 823

Virginia Tech Intellectual Properties Inc.

patents

1 out of 15,988

University of California

patents

1 out of 8,743

US Government as Represented by the Secretary of the Army

patents

4. 2 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 2000-2019

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10406219 - Multivalentvaccine for protection against mycobacterial infections and methods of using the same (2019-09-10),

2. 7364745 - Development of a live, attenuated, recombinant vaccine for Brucellosis (2008-04-29),

3. 6811787 - Over-expressing homologous antigen vaccine and a method of making the same (2004-11-02),

4. 6444445 - Live vaccine against Brucellosis (2002-09-03),

5. 6264952 - Method for protecting a mammalian host against infection by Brucella (2001-07-24),

6. 6149920 - Over-expressing homologous antigen vaccine and a method of making the (2000-11-21),

Title: Gerhardt G Schurig: Innovator in Vaccine Development

Introduction

Gerhardt G Schurig is a notable inventor based in Blacksburg, VA (US), recognized for his contributions to vaccine development. He holds a total of 6 patents, showcasing his innovative approach to addressing significant health challenges.

Latest Patents

Among his latest patents is a multivalent vaccine designed for protection against mycobacterial infections. This vaccine expresses at least one heterologous antigen and serves as an environmentally safe bivalent solution for simultaneous protection against infections. Specifically, it comprises a strain transformed with a vector that expresses at least one antigen, optimized for the strain. Notably, the strain is RB51 leuB, and the antigens include Ag85B, Rv2660c, and ESAT6. Another significant patent involves the development of a live, attenuated, recombinant vaccine for Brucellosis. This vaccine utilizes a recombinant, attenuated strain with a deficiency in carboxyl-terminal protease activity, aimed at preventing or treating Brucellosis.

Career Highlights

Gerhardt has worked with Virginia Tech Intellectual Properties, Inc., where he has contributed to various innovative projects. His work has significantly impacted the field of vaccine research and development.

Collaborations

Throughout his career, Gerhardt has collaborated with notable individuals such as Stephen M Boyle and Nammalwar Sriranganathan, enhancing the scope and impact of his research.

Conclusion

Gerhardt G Schurig's work in vaccine development exemplifies his commitment to advancing public health through innovation. His patents reflect a deep understanding of complex biological challenges and a dedication to finding effective solutions.